ArticleFrontiers in psychiatry2026
Cognitive behavioral therapy combined with aripiprazole in the treatment of schizophrenia: effects on cognitive function and psychological state.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study is to assess the effects of cognitive behavioral therapy (CBT) combined with aripiprazole on clinical symptoms, cognitive function, and emotional state in patients with schizophrenia. Methods: A single-center retrospective controlled design was used, with data from the electronic medical records of the psychiatry department of Liupanshui Shuikuang hospital. A total of 168 patients were included and divided into two groups based on whether they received structured CBT intervention: the combined treatment group (aripiprazole + CBT) and the monotherapy group (aripiprazole only), with 84 patients in each group. Propensity score matching was used to reduce bias, and the clinical symptoms, cognitive function, and emotional state of patients were evaluated at baseline (T0), 3 months (T1), and 6 months (T2). Results: The combined treatment group showed significant improvements in Positive and Negative Syndrome Scale (PANSS) total score, Montreal Cognitive Assessment (MoCA) score, Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder 7 (GAD-7) compared to the monotherapy group (P < 0.05). In terms of quality of life, the combined treatment group showed significantly greater improvement in Schizophrenia Quality of Life Scale (SQLS) total score compared to the monotherapy group (P = 0.006). Multivariate regression analysis revealed that CBT combined treatment significantly enhanced the improvement in PANSS total score and MoCA score, and was associated with reductions in depression and anxiety symptoms. An increase in treatment frequency and intensity further enhanced efficacy. Subgroup analysis showed better treatment responses in younger patients and those with a shorter disease duration. Conclusion: CBT combined with aripiprazole significantly improves the psychiatric symptoms, cognitive function, and emotional state of patients with schizophrenia, and the frequency and intensity of treatment have a positive impact on efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.